Third-Generation Transcatheter Aortic Heart Valve with Reverse Parachute Sealing Cuff in Patients with Aortic Valve Disease - 03/04/24

Doi : 10.1016/j.hlc.2023.11.019

Ganeev Malhotra, MBBS, FRACP ^a,^b, Chris M.W. Cole, MBBS, FRACS ^a,^b, Stephen V. Cox, MBBS, FRACP ^a,^b, Jordan D.W. Ross, MBBS, FRACS ^a,^b, Mark Dooris, MBBS, FRACP ^b,^c, Peter T. Moore, MBBS, FRACP ^a,^b, Adrian A. Chong, MBBS, FRACP ^a,^b,^c, Arun Dahiya, MBBS, FRACP ^a,^b, Kellee Korver, BN ^a,^b, Sam M. Hayman, MBBS, MSc, FRACP ^b,^c,^d, Anthony C. Camuglia, MBBS, MHA, FRACP ^a,^b,^c,^⁎
^a Division of Heart Lung and Critical Care, Princess Alexandra Hospital, Brisbane, QLD, Australia
^b University of Queensland, Brisbane, QLD, Australia
^c Mater Hospital and Health Service, Brisbane, QLD, Australia
^d Royal Brisbane and Women’s Hospital, Brisbane, QLD, Australia

^∗Corresponding author at: Division of Heart Lung and Critical Care, Princess Alexandra Hospital, Ipswich Road, Woolloongabba, Brisbane, QLD 4102Division of Heart Lung and Critical CarePrincess Alexandra HospitalIpswich Road, WoolloongabbaBrisbaneQLD4102

Abstract

Background

The Navitor (Abbott Inc, IL, USA) transcatheter heart valve is a novel third-generation self-expanding bioprosthesis with specific features to mitigate paravalvular regurgitation (PVR). Owing to its novelty, there is a paucity of data on its application in clinical practice.

Methods

Consecutive cohort analysis of the use of the Navitor system in an as-treated clinical setting at a quaternary heart hospital.

Results

Sixty consecutive non-clinical trial patients treated with Navitor were identified. All patients underwent a successful procedure. The mean age was 79.3 years (±SD 7.82), 56.67% (n=34) were female, and the mean STS score was 4.87 (±SD 5.70). At 30 days post-procedure, all patients were alive with no readmissions for heart failure. One patient had a major vascular complication (1.7%). Four patients (7.14% of patients without a pre-existing pacemaker) received a new permanent pacemaker. Two patients (3.4%) had a non-disabling stroke. PVR at 30 days was trivial or none in 75% of patients, and no patient had worse than mild PVR.

Conclusions

The Navitor system in this as-treated cohort was associated with favourable clinical, haemodynamic, and safety outcomes.

Le texte complet de cet article est disponible en PDF.

Keywords : Transcatheter aortic valve replacement, TAVR, Transcatheter aortic valve implantation, TAVI, Self-expanding valve, Transcatheter heart valve, THV

Plan

Export

Vol 33 - N° 3

P. 324-331 - mars 2024 Retour au numéro

Article précédent

Acute Kidney Injury Following Transcatheter Aortic Valve Implantation—A Contemporary Perspective of Incidence, Predictors, and Outcomes
Anant D. Butala, Shane Nanayakkara, Rohan V. Navani, Sonny Palmer, Samer Noaman, Kawa Haji, Nay M. Htun, Antony S. Walton, Dion Stub

| Article suivant

Sex- and Age-Specific Differences in Risk Profiles and Early Outcomes in Adults With Acute Coronary Syndromes
Lee Nedkoff, Melanie Greenland, Karice Hyun, Jasmin P. Htun, Julie Redfern, Samantha Stiles, Frank Sanfilippo, Tom Briffa, Derek P. Chew, David Brieger

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

connectez-vous ou créez un compte

Third-Generation Transcatheter Aortic Heart Valve with Reverse Parachute Sealing Cuff in Patients with Aortic Valve Disease - 03/04/24

Abstract

Background

Methods

Results

Conclusions

Plan

Export citations

Fichier

Contenu

Accès rapides

Mon compte

Aide & support

Plateformes Elsevier Masson

Déclaration CNIL